First Time Loading...

Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 171 JPY +0.14% Market Closed
Updated: Dec 4, 2023

Intrinsic Value

Valuation History
Takeda Pharmaceutical Co Ltd

Historical Profit
Current Valuation
Price & Value Correlation
Value CAGR
Calculating
Intrinsic Value History...

Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.

Fundamental Analysis

2024-Q2 Earnings Call
NEW
Artifical Intelligence Analysis

Takeda Forecasts Growth Amid Challenges
Takeda Forecasts Growth Amid Challenges

Takeda Pharmaceutical's Q2 earnings revealed a mixed picture: a 2.1 trillion JPY revenue with a full-year forecast increase, countered by a profit forecast reduction due to noncore items impacting the quarter. The core operating profit margin target remains on track at 28%, aiming for a full-year target of 1,015 billion JPY. Takeda anticipates a growth return between 2024-2025, although the timeline may be tight due to potential fluctuations. The company's recent FDA approval for ENTYVIO's subcutaneous administration, a dengue vaccine recommendation from WHO, and robust pipeline milestones bolster their positive outlook. However, margin pressures from product mix changes and competition in the ulcerative colitis treatment market are important considerations for investors.

Financials
NEW
NEW

Balance Sheet Decomposition
Takeda Pharmaceutical Co Ltd

Current Assets 2.5T
Cash & Short-Term Investments 334B
Receivables 788B
Other Current Assets 1.3T
Non-Current Assets 12.4T
Long-Term Investments 416B
PP&E 1.9T
Intangibles 9.7T
Other Non-Current Assets 396B
Current Liabilities 2.4T
Accounts Payable 421B
Other Current Liabilities 1.9T
Non-Current Liabilities 5.4T
Long-Term Debt 4.4T
Other Non-Current Liabilities 1T
Efficiency
Fundamental Scores

Profitability Score
Profitability Due Diligence

Takeda Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
ROIC is Increasing
55/100
Profitability
Score

Takeda Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
36/100
Solvency
Score

Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Takeda Pharmaceutical Co Ltd

Wall Street analysts forecast Takeda Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Takeda Pharmaceutical Co Ltd is 4 854.63 JPY with a low forecast of 4 141 JPY and a high forecast of 6 090 JPY.

Lowest
Price Target
4 141 JPY
1% Downside
Average
Price Target
4 854.63 JPY
16% Upside
Highest
Price Target
6 090 JPY
46% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Return Decomposition
Main factors of price return

What is price return decomposition?

Price
Takeda Pharmaceutical Co Ltd

1M 1M
+1%
6M 6M
-7%
1Y 1Y
+8%
3Y 3Y
+20%
5Y 5Y
+23%
10Y 10Y
+21%
Annual Price Range
4 171
52w Low
3 873.5283
52w High
4 860
Price Metrics
Average Annual Return -2.37%
Standard Deviation of Annual Returns 14.98%
Max Drawdown -37%
Shares Statistics
Market Capitalization 6.5T JPY
Shares Outstanding 1 571 786 000
Percentage of Shares Shorted
N/A

News

Last Video News
Takeda Pharmaceutical Co Ltd

Other Videos

Company Profile

Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd

Country

Japan

Industry

Pharmaceuticals

Market Cap

6.5T JPY

Dividend Yield

4.51%

Description

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,347 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Contact

TOKYO-TO
Chuo-Ku
4F, 2-1-1, Nihombashihon-cho
+81332782111.0
https://www.takeda.com/

IPO

1949-05-16

Employees

47 347

Officers

Pres, CEO & Representative Director
Mr. Christophe Weber
CFO & Representative Director
Mr. Constantine Saroukos
Pres of R&D and Representative Director
Dr. Andrew S. Plump
Chair of Management Board
Dr. Seigo Izumo
Member of Management Board
Mr. Haruhiko Hirate
Member of Management Board and Head of R&D Global Science & Biomedical Policy
Salvatore Alesci
Show More
Chief Accounting Officer & Corp. Controller
Norimasa Takeda
Sr. VP of Corp. Fin. & Controlling Department
Mr. Iwaaki Taniguchi
Chief Data & Technology Officer
Mr. Gabriele Ricci
Global Head of Investor Relations & Global Fin.
Mr. Christopher David O'Reilly
Show Less

See Also

Discover More
What is the Intrinsic Value of one Takeda Pharmaceutical Co Ltd stock?

The intrinsic value of one Takeda Pharmaceutical Co Ltd stock under the Base Case scenario is 5 469.04 JPY.

Is Takeda Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 4 171 JPY, Takeda Pharmaceutical Co Ltd is Undervalued by 24%.